logo-loader
viewCyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals CEO reveals key milestone data

Cyclacel Pharmaceuticals, Inc (NASDAQ:CYCC) CEO Spiro Rombotis joined Proactive at the Biotech Showcase 2020 in San Francisco. The New Jersey-based company recently announced preliminary data from two of the company’s Phase 1 studies aiming to treat patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes and chronic lymphocytic leukemia.

Quick facts: Cyclacel Pharmaceuticals Inc

Price: 0.6847 USD

NASDAQ:CYCC
Market: NASDAQ
Market Cap: $11.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Empower Clinics looking to attack opioid crisis with...

Empower Clinics (CSE:CBDT-OTC: EPWCF) Chairman and CEO Steven McAuley joined Steve Darling from Proactive in Toronto to discuss the company creating a division focussing on psilocybin and psychedelics aka magic mushrooms. McAuley telling Proactive how key this may become considering the...

3 hours, 5 minutes ago

2 min read